Once-Daily Insulin in Prefilled Pen Gets FDA Nod

Share this content:

Sanofi announced that the Food and Drug Administration (FDA) has approved once-daily Toujeo (insulin glargine [rDNA origin]) injection 300 U/mL to improve glycemic control in adults with type 1 and type 2 diabetes mellitus.

The approval of Toujeo was based on an FDA review of data from the EDITION clinical trial program that was comprised of a series of international Phase 3 studies on the safety and efficavy of Toujeo in over 3,500 adults with type 1 and type 2 diabetes. All studies met the primary study endpoints by demonstrating similar blood sugar control with once-daily Toujeo compared to once-daily Lantus (insulin glargine [rDNA origin]; Sanofi) injection 100 U/mL, including an open-label, randomized, active-control, parallel, treat-to-target studies of up to 26 weeks of duration with six months safety extension.

Toujeo will be available in the Toujeo SoloSTAR, a disposable prefilled pen with 450 units of Toujeo. It is expected to be available at the beginning of the second quarter of 2015.

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Pharmacists Should Counsel Patients Fasting for Ramadan

Pharmacists Should Counsel Patients Fasting for Ramadan

Pharmacists can suggest adjustments for meds taken several times per day, those affected by food intake

AUA: Many Have Unused Opioids After Urologic Procedures

AUA: Many Have Unused Opioids After Urologic Procedures

Patients use just over half of initial prescription; highest percentage of unused meds for cystectomy

Over Half of Young Adult Smoke Volume Exposure From Hookahs

Over Half of Young Adult Smoke Volume Exposure ...

Toxicant exposure to tar, carbon monoxide, nicotine lower, but still substantial, compared to cigarettes

is free, fast, and customized just for you!

Already a member?

Sign In Now »